Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease
説明
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background:</jats:title><jats:p>We report on a double‐blind, crossover pilot trial for the treatment of rapid eye movement behavior disorder (RBD) in 12 patients with Parkinson's disease in whom conventional therapy failed.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>We employed a patch of the cholinesterase inhibitor rivastigmine at a dose of 4.6 mg/24 hours for 3 weeks compared with placebo to reduce the frequency of RBD episodes. The number of RBD episodes was monitored by diaries of bed partners.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>Rivastigmine was well tolerated in most patients, with minor side effects, mainly related to peripheral cholinergic action, and significantly reduced the mean frequency of RBD episodes during the observation time.</jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p>The results of this pilot trial need to be confirmed by further studies on a larger number of patients. © 2012 Movement Disorder Society</jats:p></jats:sec>
収録刊行物
-
- Movement Disorders
-
Movement Disorders 27 (4), 559-561, 2012-01-30
Wiley
